A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

NCT01321554 ·Status: COMPLETED ·Phase: PHASE3

Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)

NCT04858867 ·Status: RECRUITING ·Phase: NA

Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer

NCT05789667 ·Status: RECRUITING

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

NCT02430714 ·Status: COMPLETED

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

NCT00095836 ·Status: COMPLETED ·Phase: PHASE2

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

NCT04619316 ·Status: UNKNOWN ·Phase: PHASE2

Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

NCT00389441 ·Status: COMPLETED ·Phase: PHASE2

The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.

NCT04447183 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.

NCT06134830 ·Status: NOT_YET_RECRUITING

Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer

NCT02390934 ·Status: COMPLETED ·Phase: PHASE2

Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment

NCT03624751 ·Status: ACTIVE_NOT_RECRUITING

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

NCT05733013 ·Status: RECRUITING

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

NCT05994365 ·Status: RECRUITING

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

NCT03630120 ·Status: TERMINATED ·Phase: PHASE2

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

NCT04554680 ·Status: UNKNOWN ·Phase: PHASE2

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

NCT01876784 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

NCT00098345 ·Status: COMPLETED ·Phase: PHASE2

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

NCT02393690 ·Status: COMPLETED ·Phase: PHASE2

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

NCT04137185 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

NCT00970359 ·Status: COMPLETED ·Phase: NA

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

NCT00094055 ·Status: COMPLETED ·Phase: PHASE2

Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma

NCT04354324 ·Status: RECRUITING ·Phase: NA

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

NCT00887107 ·Status: COMPLETED ·Phase: PHASE2

Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up

NCT04290663 ·Status: RECRUITING ·Phase: PHASE3

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

NCT05660954 ·Status: COMPLETED ·Phase: PHASE2